e19100 Background: Real-world data on lymphoma subtypes from low-income countries remain limited, particularly regarding treatment patterns and outcomes across diverse histologies. This study evaluates the clinical characteristics, treatment responses, and outcomes of patients with Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) subtypes managed in routine clinical practice. Methods: This retrospective real-world study included 450 patients diagnosed with lymphoma between January 2019 to December 2025 at MNJ institute of oncology and regional cancer centre, India. Histological subtypes analyzed included Hodgkin lymphoma, non-Hodgkin lymphoma (diffuse large B-cell, follicular, mantle cell, anaplastic large cell lymphoma ALCL, T-cell NHL), plasmablastic lymphoma, and Burkitt’s lymphoma. Diagnosis was established using histopathology and immunohistochemistry. Treatment regimens were selected based on institutional protocols and resource availability. Treatment response was assessed using standard clinical and radiological criteria. Results: A total of 427 patients included in the final analysis, with a median age of 40 years. 23 patients excluded. Hodgkin lymphoma (n = 127) constituted the largest proportion of cases, followed by non-Hodgkin lymphoma (n = 107), among which follicular lymphoma (n = 57) and diffuse large B-cell lymphoma (n = 55) were the most common subtypes. Aggressive lymphomas included Burkitt’s lymphoma (n = 20), plasmablastic lymphoma (n = 7), mantle cell lymphoma (n = 12), and T-cell non-Hodgkin lymphoma (n = 13), the majority of which presented with advanced-stage disease. The cohort shows a male predominance, with 274 males and 153 females. stage IV disease observed in 173 patients at diagnosis. At last follow-up, 272 patients were alive, while 71 patients had died due to disease progression or chemotherapy-related toxicity. Notably, 84 patients (19%) defaulted treatment, reflecting significant challenges related to treatment adherence in a resource-constrained setting. 20% of defaulted patients were confirmed alive, suggesting potential for recovery with appropriate strategies, commonly seen in Hodgkin’s lymphoma, Pediatric age group and who presented with poor initial response. Relapse Rate is 17%. Among relapse patients 60% are alive with effective salvage regimens are ICE, GDP, DHAP+/- Rituximab, 3% are dead, 37% defaulted. Overall survival till December 2025 is 70% Hodgkin's (82%) > Follicular (79%) > DLBCL (65%). Advanced stage, older age, and treatment default were independent predictors of poorer survival. Conclusions: This retrospective analysis of 427 lymphoma patients provides comprehensive insights into treatment outcomes, relapse patterns, and survival in a real-world clinical setting. Outcome n (%) Overall Default rate 84/427 (19%) Alive 272/427 (63.7%) Dead 71/427 (16.6%) Response to treatment 276/427(64.6%) Relapse 72/427 (16.9%)
Vasagiri et al. (Thu,) studied this question.